Avid Bioservices (CDMO) Misses Q2 EPS by 17c

Avid Bioservices (NASDAQ: CDMO) reported Q2 EPS of ($0.27), $0.17 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $33.5 million versus the consensus estimate of $33.8 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat